A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

During the time period 2020 to 2023, approximately 1 in 5 youth and 1 in 3 adults with type 1 diabetes and severe obesity ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

So, should you buy the dip in Viking Therapeutics now? Here's what you need to know. Viking Therapeutics is a clinical-stage ...

The annual prevalence increased to 0.4% by 2022, with an estimated 854,728 adults without diabetes using GLP-1 RAs. HealthDay News — Among US adults without diabetes, the use of glucagon-like ...